MedTrace Logo

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

NCT01760642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-05-26

No results posted yet for this study

Summary

Identification and evaluation of endogenous markers for the assessment of CYP3A activity in female subjects using metabolomics

Conditions

  • Healthy

Interventions

DRUG

Midazolam

Midazolam 3 mg IV

DRUG

Ketoconazole

ketoconazole 400 mg PO

DRUG

Rifampicin

Rifampicin 600 mg PO

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Joo-Youn Cho, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01760642 on ClinicalTrials.gov